You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康華生物(300841.SZ):公司研發的重組六價諾如病毒疫苗具有較大的臨牀價值和市場空間
格隆匯 07-11 09:00

格隆匯7月11日丨康華生物(300841.SZ)近期在接待機構投資者調研時表示,諾如病毒是隸屬於杯狀病毒科諾如病毒屬的單鏈正股RNA病毒,病毒分子進化快、劑量感染低、持續排毒久、傳播途徑多,是導致非細菌性急性腸胃炎的主要病原體。諾如病毒主要傳播途徑為人傳人、經食物和經水傳播,其感染在一年四季均有流行,可以造成各個年齡段的羣體暴發流行。諾如具有高度傳染性且感染劑量較低,通常18-100個病毒即可造成人感染,在人口密集的環境,如學校、餐館、養老院和醫院等全封閉或半封閉機構中急性胃腸炎的暴發較為常見。目前針對諾如病毒感染的治療手段中尚無特效的抗病毒藥物,並且沒有用於預防接種的疫苗產品。

公司研發的重組六價諾如病毒疫苗含六種病毒主要流行基因型的重組病毒樣顆粒抗原,具有較大的臨牀價值和市場空間。該在研疫苗於2023年2月在澳大利亞獲得I期臨牀試驗許可,正在進行試驗相關準備工作;考慮到疫苗的研發週期較長,需要經過臨牀試驗和監管機構審評審批後方可上市,公司亦將對該產品後續研發進展進行及時的披露。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account